Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate and testosterone for bone density in male patients with major thalassemia
IRCT20201110049334N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of alendronate and testosterone in beta thalassemia major, Hypogonadism and low bone mineral density (4 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Bone density. Started Dec 2021; status: completed.
02
Drugs
alendronatetestosterone
03
Conditions
beta thalassemia majorHypogonadismlow bone mineral density
Beyond the preview
Go deeper on IRCT20201110049334N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201110049334N2.